Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

An Integrated Epigenomic and Genomic View on Phyllodes and Phyllodes-like Breast Tumors

ABSTRACT: An Integrated Epigenomic and Genomic View on Phyllodes and Phyllodes-like Breast Tumors

PROVIDER: PRJNA743886 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

An Integrated Epigenomic and Genomic View on Phyllodes and Phyllodes-like Breast Tumors

Project description:Phyllodes tumor of the breast (human) as well as a set of related tumors Phyllodes tumor, Fibroadenoma, Breast Cancer

2021-07-07 | GSE179458 | GEO

An Integrated Epigenomic and Genomic View on Phyllodes and Phyllodes-like Breast Tumors.

Project description:Fibroepithelial lesions (FL) of the breast, in particular, phyllodes tumors (PT) and fibroadenomas, pose a significant diagnostic challenge. There are no generally accepted criteria that distinguish benign, borderline, malignant PT and fibroadenomas. Combined genome-wide DNA methylation and copy number variant (CNV) profiling is an emerging strategy to classify tumors. We compiled a series of patient-derived archival biopsy specimens reflecting the FL spectrum and histological mimickers including clinical follow-up data. DNA methylation and CNVs were determined by well-established microarrays. Comparison of the patterns with a pan-cancer dataset assembled from public resources including "The Cancer Genome Atlas" (TCGA) and "Gene Expression Omnibus" (GEO) suggests that FLs form a methylation class distinct from both control breast tissue as well as common breast cancers. Complex CNVs were enriched in clinically aggressive FLs. Subsequent fluorescence in situ hybridization (FISH) analysis detected respective aberrations in the neoplastic mesenchymal component of FLs only, confirming that the epithelial component is non-neoplastic. Of note, our approach could lead to the elimination of the diagnostically problematic category of borderline PT and allow for optimized prognostic patient stratification. Furthermore, the identified recurrent genomic aberrations such as 1q gains (including MDM4), CDKN2a/b deletions, and EGFR amplifications may inform therapeutic decision-making.

| S-EPMC8833410 | biostudies-literature

lncRNAs differentially expressed in benign and malignant phyllodes tumors [array]

Project description:To investigate the pathogenesis of malignant phyllodes tumors of the breast, we used lncRNA+mRNA microarray expression profiling as a platform to investigate lncRNAs that play a key role in the malignant progression of phyllodes tumors of the breast.A total of 4 cases of breast fibroadenomas, 6 cases of benign phyllodes tumors and 6 cases of malignant phyllodes tumors were included. Fibroadenomas and benign phyllodes tumors were used as controls to screen out significantly differentially expressed lncrnas in malignant phyllodes tumors.

2024-06-20 | GSE235267 | GEO

Classification of fibroadenomas and phyllodes tumors

Project description:WG-DASL expression of breast fibroepithelial lesions Breast fibroepithelial lesions are biphasic tumors and include fibroadenomas and phyllodes tumors. Fibroadenomas are clinically benign while phyllodes tumors are more unpredictable in biological behavior, with potential for recurrence. Differentiating the tumors may be challeneging when they have overlapping clinical and histological features especially on the core biopsies

2016-04-29 | GSE78071 | GEO

DNA methylation profiling of phyllodes tumours determines a signature of malignancy and delineates from metaplastic breast carcinoma

Project description:Genome wide DNA methylation profiling of phyllodes tumour, fibroadenoma and metaplastic breast cancer samples. The Illumina Infinium Methylation EPIC v1.0 BeadChip Array was used to obtain DNA methylation profiles across approximately 866,000 CpGs from primary tumours. Samples included a range of grades of phyllodes tumours (n=29), fibroadenoma (n=2), and metaplastic breast cancer (n=2).

2023-12-15 | GSE231574 | GEO

Integrated epigenomic and transcriptomic profiling of terminal human erythropoiesis

Project description:Integrated epigenomic and transcriptomic profiling of terminal human erythropoiesis

| PRJNA475760 | ENA

lncRNAs differentially expressed in benign and malignant phyllodes tumors [array]

Project description:lncRNAs differentially expressed in benign and malignant phyllodes tumors [array]

| PRJNA985635 | ENA

CD146 accelerates malignant progression of phyllodes tumor cells

Project description:Breast malignant phyllodes tumors (PTs) are rapid-progressing tumors, known to lack effective treatment and suitable prognostic markers as well as elaborate studies. Herein,we found that level of CD146 is progressively elevated with malignant progression of PTs and is an independent predictor for prognosis of PT patients.Mechanistically, CD146 activates the PI3K/AKT signaling pathway, thereby enhancing malignant behaviors of PT cells.This study unveils a CD146-PI3K/AKT axis in modulating the malignant progression of PTs, and open avenues to develop a novel target for precise prognosis and treatment for breast malignant PTs.

2023-12-01 | GSE227380 | GEO

Hylodes phyllodes isolate:MTR 11656

Project description:Hylodes phyllodes isolate:MTR 11656 Targeted Locus (Loci)

| PRJNA338562 | ENA

Integrated epigenomic and transcriptomic profiling of terminal human erythropoiesis [TMCC2]

Project description:Integrated epigenomic and transcriptomic profiling of terminal human erythropoiesis [TMCC2]

| PRJNA508967 | ENA